Are you looking to add some growth shares to your investment portfolio in June?
If you are, then the four highly rated ASX growth shares listed below could be worth considering.
Here's what you need to know about them:
Aristocrat Leisure Limited (ASX: ALL)
The first ASX growth share that could be a buy is Aristocrat Leisure. It is one of the world's leading gaming technology companies. It has a world class portfolio of pokie machines, a lucrative digital business, and a growing real money gaming business.
Analysts at Citi are very positive on the company. Particularly given its strong performance in the first half of FY 2024 and management's confidence in its outlook.
Citi has a buy rating and a $53.00 price target on Aristocrat Leisure's shares.
Pro Medicus Limited (ASX: PME)
Goldman Sachs thinks Pro Medicus is a top ASX growth share to buy. It is a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation solutions across the globe.
Goldman is very positive on the company's outlook. It notes that it sees "PME as the clear incumbent technology leader in a growing market with a strong financial profile and significant AI upside."
The broker has a buy rating and a $136.00 price target on its shares.
ResMed Inc. (ASX: RMD)
A third ASX growth share that has been tipped as a buy is ResMed. It is a sleep treatment-focused medical device company.
ResMed has been growing at a strong rate for over a decade. But if you thought its growth was coming to an end, think again. That's because its industry-leading products have a massive market opportunity. Management estimates that there are 1 billion people impacted by sleep apnoea worldwide, with only ~20% of these sufferers currently diagnosed.
Ord Minnett is bullish on ResMed and has an accumulate rating and a $40.00 price target on its shares.
TechnologyOne Ltd (ASX: TNE)
A final ASX growth share for investors to look at in June is TechnologyOne. It is Australia's largest enterprise software company with locations across six countries. It provides a global SaaS ERP solution that transforms business and makes life simple for users.
Analysts at Morgans were impressed with the company's half-year results this month. In fact, the broker believes that the company's profit growth is about to go up a gear. Particularly given its successful transition to a software-as-a-service business model.
Morgans currently has an add rating and a $20.50 price target on its shares.
